Insights
Search Results
Client Highlights
6.17.25
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly
On June 17, 2025, Eli Lilly and Company and Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for Lilly to acquire Verve. Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction.
Client Highlights
1.09.25
Wilson Sonsini Advises General Atlantic on IP Matters Related to Verdiva Bio’s Formation and $410 Million Series A
On January 9, 2025, Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. Verdiva launched with an oversubscribed Series A financing of $411 million, co-led by General Atlantic and Forbion, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital (collectively, “the Investor Group”). Wilson Sonsini Goodrich & Rosati advised General Atlantic on IP matters related to Verdiva’s formation and Series A funding round.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
Client Highlights
2.29.24
Wilson Sonsini Advises Janux Therapeutics on IP Matters Related to $296.5 Million Underwritten Public Offering
On February 29, 2024, Janux Therapeutics (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, announced the pricing of an underwritten public offering of 4,440,851 shares of its common stock at a public offering price of $46.50 per share and pre-funded warrants to purchase 1,935,483 shares of common stock at a price of $46.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Janux from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding the exercise of any pre-funded warrants, are expected to be approximately $296.5 million. In addition, Janux has granted the underwriters a 30-day option to purchase up to an additional 956,450 shares of its common stock. All of the shares to be sold in the offering are to be sold by Janux. The offering is expected to close on or about March 4, 2024, subject to customary closing conditions. Janux intends to use the net proceeds from the offering to advance clinical development of its internal product pipeline and for general corporate purposes.
Client Highlights
11.14.23
Wilson Sonsini Advises CARGO Therapeutics on IP Matters Related to $281 Million IPO
On November 10, 2023, CARGO Therapeutics, a clinical-stage biotech specializing in cancer treatments, made its debut on the Nasdaq Global Select Market under the ticker "CRGX" after successfully raising approximately $281 million through its initial public offering (IPO). The company priced its IPO at $15 per share, issuing 18.75 million shares. Wilson Sonsini Goodrich & Rosati advised CARGO on patent and technology transactions matters leading up to and with respect to the IPO.
Client Highlights
9.28.23
Wilson Sonsini Advises Azurity on IP Matters Related to Slayback Pharma Acquisition
On September 27, 2023, Azurity Pharmaceuticals, Inc. announced the closing of its acquisition of Slayback Pharma LLC from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is now a wholly-owned subsidiary of Azurity. Wilson Sonsini Goodrich & Rosati advised Azurity on IP matters related to the transaction.
The acquisition brings together companies with complementary strengths, enhancing Azurity’s ability to realize its purpose of Serving Overlooked Patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.
The Wilson Sonsini team that advised Azurity on IP matters related to the acquisition includes Clark Lin, Wendy Devine, Ying Chen, Shu Boboila, Xiaoyang Tang, Kevin Tylock, and Johnson Truong.
The acquisition brings together companies with complementary strengths, enhancing Azurity’s ability to realize its purpose of Serving Overlooked Patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.
The Wilson Sonsini team that advised Azurity on IP matters related to the acquisition includes Clark Lin, Wendy Devine, Ying Chen, Shu Boboila, Xiaoyang Tang, Kevin Tylock, and Johnson Truong.